The table below shows Autolus Therapeutics plc's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$283.57M
-$206.27M
-$145.59M
-$112.31M
-$117.86M
-$117.76M
Capital expenditure
$19.04M
$22.07M
$10.99M
$10.84M
$8.86M
$14.68M
Investing cash flow
$158.46M
-$394.55M
-$10.99M
-$10.84M
-$8.86M
-$14.68M
Dividends paid
-
-
-
-
AUTL operating cash flow (10-K history)
Autolus Therapeutics plc reported operating cash flow of -$283.57M for fiscal year 2025. That is down 37.5% from -$206.27M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$9.85M (FY 2016) to -$283.57M. Figures come from the company's audited annual reports as filed with the SEC.